Suppr超能文献

支气管扩张剂预后肺功能作为肺健康研究死亡率的预测因子。

Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study.

机构信息

University of Kentucky, College of Public Health, Lexington, KY, USA.

出版信息

Respir Res. 2011 Oct 12;12(1):136. doi: 10.1186/1465-9921-12-136.

Abstract

BACKGROUND

Chronic obstructive pulmonary disease (COPD) is supposed to be classified on the basis of post-bronchodilator lung function. Most longitudinal studies of COPD, though, do not have post-bronchodilator lung function available. We used pre-and post bronchodilator lung function data from the Lung Health Study to determine whether these measures differ in their ability to predict mortality.

METHODS

We limited our analysis to subjects who were of black or white race, on whom we had complete data, and who participated at either the 1 year or the 5 year follow-up visit. We classified subjects based on their baseline lung function, according to COPD Classification criteria using both pre- and post-bronchodilator lung function. We conducted a survival analysis and logistic regression predicting death and controlling for age, sex, race, treatment group, smoking status, and measures of lung function (either pre- or post-bronchodilator. We calculated hazard ratios (HR) with 95% confidence intervals (CI) and also calculated area under the curve for the logistic regression models.

RESULTS

By year 15 of the study, 721 of the original 5,887 study subjects had died. In the year 1 sample survival models, a higher FEV1 % predicted lower mortality in both the pre-bronchodilator (HR 0.87, 95% CI 0.81, 0.94 per 10% increase) and post-bronchodilator (HR 0.84, 95% CI 0.77, 0.90) models. The area under the curve for the respective models was 69.2% and 69.4%. Similarly, using categories, when compared to people with "normal" lung function, subjects with Stage 3 or 4 disease had similar mortality in both the pre- (HR 1.51, 95% CI 0.75, 3.03) and post-bronchodilator (HR 1.45, 95% CI 0.41, 5.15) models. In the year 5 sample, when a larger proportion of subjects had Stage 3 or 4 disease (6.4% in the pre-bronchodilator group), mortality was significantly increased in both the pre- (HR 2.68, 95% CI 1.51, 4.75) and post-bronchodilator (HR 2.46, 95% CI 1.63, 3.73) models.

CONCLUSIONS

Both pre- and post-bronchodilator lung function predicted mortality in this analysis with a similar degree of accuracy. Post-bronchodilator lung function may not be needed in population studies that predict long-term outcomes.

摘要

背景

慢性阻塞性肺疾病(COPD)应根据支气管扩张剂后肺功能进行分类。然而,大多数 COPD 的纵向研究并没有支气管扩张剂后肺功能的资料。我们使用来自肺健康研究的支气管扩张剂前后肺功能数据,来确定这些指标在预测死亡率方面的能力是否存在差异。

方法

我们将分析仅限于黑人和白人种族的受试者,他们有完整的数据,并且在第 1 年或第 5 年随访时参加了研究。我们根据他们的基线肺功能,根据 COPD 分类标准,使用支气管扩张剂前后的肺功能进行分类。我们进行了生存分析和逻辑回归预测死亡,并控制年龄、性别、种族、治疗组、吸烟状况以及肺功能指标(支气管扩张剂前后)。我们计算了危险比(HR)和 95%置信区间(CI),并计算了逻辑回归模型的曲线下面积。

结果

在研究的第 15 年,5887 名研究对象中有 721 人死亡。在第 1 年的生存模型中,FEV1%预计值越高,支气管扩张剂前后模型的死亡率越低(支气管扩张剂前:HR 0.87,95%CI 0.81,0.94,每增加 10%;支气管扩张剂后:HR 0.84,95%CI 0.77,0.90)。各自模型的曲线下面积分别为 69.2%和 69.4%。同样,使用分类方法,与“正常”肺功能的人相比,3 或 4 期疾病的患者在支气管扩张剂前后模型中具有相似的死亡率(支气管扩张剂前:HR 1.51,95%CI 0.75,3.03;支气管扩张剂后:HR 1.45,95%CI 0.41,5.15)。在第 5 年的样本中,当更多的患者患有 3 或 4 期疾病(支气管扩张剂前组的 6.4%)时,在支气管扩张剂前后模型中,死亡率均显著增加(支气管扩张剂前:HR 2.68,95%CI 1.51,4.75;支气管扩张剂后:HR 2.46,95%CI 1.63,3.73)。

结论

在这项分析中,支气管扩张剂前后的肺功能都能以相似的准确性预测死亡率。在预测长期结果的人群研究中,可能不需要支气管扩张剂后的肺功能。

相似文献

1
Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study.
Respir Res. 2011 Oct 12;12(1):136. doi: 10.1186/1465-9921-12-136.
2
Comparison of pre- and post-bronchodilator lung function as predictors of mortality: The HUNT Study.
Respirology. 2020 Apr;25(4):401-409. doi: 10.1111/resp.13648. Epub 2019 Jul 24.
4
Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity.
COPD. 2012 Jun;9(3):276-80. doi: 10.3109/15412555.2012.654529. Epub 2012 Feb 23.
6
Bronchodilator response in the lung health study over 11 yrs.
Eur Respir J. 2005 Jul;26(1):45-51. doi: 10.1183/09031936.05.00102604.
9
Blood biomarkers as predictors of long-term mortality in COPD.
Clin Respir J. 2018 May;12(5):1891-1899. doi: 10.1111/crj.12752. Epub 2018 Jan 5.
10
Decreased Lung Function and All-Cause Mortality in HIV-infected Individuals.
Ann Am Thorac Soc. 2018 Feb;15(2):192-199. doi: 10.1513/AnnalsATS.201606-492OC.

引用本文的文献

1
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study.
Am J Respir Crit Care Med. 2025 Jul;211(7):1196-1210. doi: 10.1164/rccm.202408-1656OC.
2
Challenges and the Future of Pulmonary Function Testing in Chronic Obstructive Pulmonary Disease (COPD): Toward Earlier Diagnosis of COPD.
Tuberc Respir Dis (Seoul). 2025 Jul;88(3):413-418. doi: 10.4046/trd.2025.0009. Epub 2025 Mar 25.
3
Associations between life's essential 8 and preserved ratio impaired spirometry.
Sci Rep. 2025 Mar 10;15(1):8166. doi: 10.1038/s41598-025-90381-w.
4
GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD.
Eur Respir J. 2025 Feb 6;65(2). doi: 10.1183/13993003.01603-2024. Print 2025 Feb.
6
The prevalence and mortality risks of PRISm and COPD in the United States from NHANES 2007-2012.
Respir Res. 2024 May 15;25(1):208. doi: 10.1186/s12931-024-02841-y.
7
Prognostic models and factors identifying end-of-life in non-cancer chronic diseases: a systematic review.
BMJ Support Palliat Care. 2024 Dec 19;14(e3):e2316-e2329. doi: 10.1136/spcare-2023-004656.
8
Spirometry test values can be estimated from a single chest radiograph.
Front Med (Lausanne). 2024 Mar 6;11:1335958. doi: 10.3389/fmed.2024.1335958. eCollection 2024.
9
Systemic Markers of Lung Function and Forced Expiratory Volume in 1 Second Decline across Diverse Cohorts.
Ann Am Thorac Soc. 2023 Aug;20(8):1124-1135. doi: 10.1513/AnnalsATS.202210-857OC.
10
Extracellular Vesicle-Encapsulated microRNAs as Novel Biomarkers of Lung Health.
Am J Respir Crit Care Med. 2023 Jan 1;207(1):50-59. doi: 10.1164/rccm.202109-2208OC.

本文引用的文献

1
Deaths: final data for 2008.
Natl Vital Stat Rep. 2011 Dec 7;59(10):1-126.
2
Characterisation of COPD heterogeneity in the ECLIPSE cohort.
Respir Res. 2010 Sep 10;11(1):122. doi: 10.1186/1465-9921-11-122.
3
Chronic obstructive pulmonary disease phenotypes: the future of COPD.
Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604. doi: 10.1164/rccm.200912-1843CC. Epub 2010 Jun 3.
4
Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study.
Am J Respir Crit Care Med. 2009 Sep 1;180(5):407-14. doi: 10.1164/rccm.200812-1966OC. Epub 2009 Jun 19.
5
Bronchodilator responsiveness in patients with COPD.
Eur Respir J. 2008 Apr;31(4):742-50. doi: 10.1183/09031936.00129607. Epub 2008 Feb 6.
6
Global burden of COPD: risk factors, prevalence, and future trends.
Lancet. 2007 Sep 1;370(9589):765-73. doi: 10.1016/S0140-6736(07)61380-4.
7
Impact of bronchodilator use on the prevalence of COPD in population-based samples.
COPD. 2007 Jun;4(2):113-20. doi: 10.1080/15412550701341012.
8
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. doi: 10.1164/rccm.200703-456SO. Epub 2007 May 16.
9
Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?
Thorax. 2007 Mar;62(3):237-41. doi: 10.1136/thx.2006.068379. Epub 2006 Nov 7.
10
Asthma: defining of the persistent adult phenotypes.
Lancet. 2006 Aug 26;368(9537):804-13. doi: 10.1016/S0140-6736(06)69290-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验